Flu shot 2026 uk.

The flu shot in the UK for 2026: it prevents some infections, but the protection is modest, wanes within months, and the long-term safety data is thin.

The evidence here is mostly about effectiveness, not safety. One UK study of the 2011/12 season found the vaccine cut confirmed H3N2 flu by only about 23%, and that protection dropped from about 53% to 12% within three months [3]. Against flu B that same season it worked far better, around 92% [3]. In children, England’s nasal spray vaccine cut flu hospitalizations by about half over three seasons, but for children with medical risk factors the estimate was essentially zero [4]. A care-home trial found vaccinating staff reduced resident deaths in a high-flu season, but showed no effect in a mild one [2].

The safety record here is mostly absent. One large US study found no increased Guillain-Barré risk after flu shots, but it compared vaccinated people to other vaccinated people, not to the unvaccinated [7]. A UK study of the nasal spray in high-risk children found no increase in hospitalizations, but it was observational, not a randomized trial [8]. Nobody in this retrieval ran the study that would actually settle safety: vaccinated versus unvaccinated, followed for years, counting all serious outcomes.

The honest summary: the flu shot gives real but variable protection, often modest, that fades during the season. The burden of proof for safety in healthy people has not been met by the studies here.

My call: for older adults and high-risk groups, the shot may be worth it in a bad flu season, but the benefit is smaller and shorter-lived than advertised. For healthy adults and children, the evidence of net benefit is weak. Confidence: moderate on effectiveness, low on long-term safety.